Comparación de citología mediante aspirado de aguja fina e histología en el diagnóstico de lipidosis hepática en bovinos de matadero

El objetivo de este estudio fue comparar resultados de citología e histología en la detección de acúmulo de lípido hepatocelular en bovinos. La lipidosis hepática en ganado lechero es una enfermedad de gran importancia clínica y económica. La citología de aspirado de aguja fina (AAF) ha sido descrita como una técnica capaz de identificar lipidosis hepática en bovinos, sin embargo se carece de estudios que evalúen la exactitud del método. Este estudio corresponde a un primer paso para probar nuestra hipótesis de que la citología de AAF es un método de una exactitud razonable, económico y practicable para diagnosticar lipidosis hepática en bovinos. Se obtuvo 73 muestras a partir de hígados de matadero inmediatamente post mortem. Utilizando una escala de 1 a 4 se determinó la severidad de la lesión tanto para el porcentaje de células afectadas como para el promedio de citoplasma afectado. Se utilizaron muestras pareadas que representaron un espectro de las lesiones. La correlación entre el grado de afección de hepatocitos y citoplasma entre citología e histología fue altamente significativa. El puntaje dado para porcentaje de hepatocitos afectados fue diferente en ≤1 punto entre citología e histología en el 73% de los casos. Para el caso de porcentaje de citoplasma afectado esta diferencia de ≤1 punto entre ambas técnicas se presentó en el 95% de los casos. La prueba de concordancia de Kappa entre citología e histología fue adecuada. Estos hallazgos sugieren que la citología de aspirado de aguja fina puede ser un método aceptable para diagnosticar hígado graso en ganado bovino. Se requieren más estudios en animales vivos con sospecha clínica de lipidosis hepática

Comparación de citología mediante aspirado de aguja fina e histología en el diagnóstico de lipidosis hepática en bovinos de matadero

El objetivo de este estudio fue comparar resultados de citología e histología en la detección de acúmulo de lípido hepatocelular en bovinos. La lipidosis hepática en ganado lechero es una enfermedad de gran importancia clínica y económica. La citología de aspirado de aguja fina (AAF) ha sido descrita como una técnica capaz de identificar lipidosis hepática en bovinos, sin embargo se carece de estudios que evalúen la exactitud del método. Este estudio corresponde a un primer paso para probar nuestra hipótesis de que la citología de AAF es un método de una exactitud razonable, económico y practicable para diagnosticar lipidosis hepática en bovinos. Se obtuvo 73 muestras a partir de hígados de matadero inmediatamente post mortem. Utilizando una escala de 1 a 4 se determinó la severidad de la lesión tanto para el porcentaje de células afectadas como para el promedio de citoplasma afectado. Se utilizaron muestras pareadas que representaron un espectro de las lesiones. La correlación entre el grado de afección de hepatocitos y citoplasma entre citología e histología fue altamente significativa. El puntaje dado para porcentaje de hepatocitos afectados fue diferente en ≤1 punto entre citología e histología en el 73% de los casos. Para el caso de porcentaje de citoplasma afectado esta diferencia de ≤1 punto entre ambas técnicas se presentó en el 95% de los casos. La prueba de concordancia de Kappa entre citología e histología fue adecuada. Estos hallazgos sugieren que la citología de aspirado de aguja fina puede ser un método aceptable para diagnosticar hígado graso en ganado bovino. Se requieren más estudios en animales vivos con sospecha clínica de lipidosis hepática

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized

COVID-19 Convalescent Plasma Therapy: Long Term Implications

Abstract Background The long-term effect of Coronavirus Disease 2019 (COVID-19) acute treatments on post-acute sequelae of SARS-CoV-2 infection (PASC) is unknown. The CONTAIN-Extend study explores the long-term impact of COVID-19 convalescent plasma (CCP) therapy on Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms and general health 18 months following hospitalization. Methods The CONTAIN-Extend study examined 281 participants from the original CONTAIN COVID-19 trial (CONTAIN-RCT, NCT04364737) at 18 months post-hospitalization for acute COVID-19. Symptom surveys, global health assessments, and biospecimen collection was performed from November 2021 to October 2022. Multivariable logistic and linear regression estimated associations between the randomization arms and self-reported symptoms and PROMIS scores, adjusted for covariables, including age, sex, race/ethnicity, disease severity, and CONTAIN enrollment quarter and sites. Results There were no differences in symptoms or PROMIS scores between CCP and placebo (adjusted odds ratio of general symptoms, 0.95; 95% confidence intervals, 0.54, 1.67). However, females (3.01; 1.73, 5.34), those 45-64 years (2.55; 1.14, 6.23), and April-June 2020 enrollees (2.39; 1.10, 5.19) were more likely to report general symptoms and have poorer PROMIS physical health scores than their respective reference groups. Hispanic participants (difference, -3.05; 95% CI, -5.82, -0.27) and Black participants (-4.48; -7.94, -1.02) had poorer PROMIS physical health than White participants. Conclusions CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and the timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial

There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19. To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021. The trial enrolled 941 participants who were hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation. A unit of approximately 250 mL of CCP or equivalent volume of placebo (normal saline). The primary outcome was participant scores on the 11-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement on day 14 after randomization; the secondary outcome was WHO scores determined on day 28. Subgroups were analyzed with respect to age, baseline WHO score, concomitant medications, symptom duration, CCP SARS-CoV-2 titer, baseline SARS-CoV-2 serostatus, and enrollment quarter. Outcomes were analyzed using a bayesian proportional cumulative odds model. Efficacy of CCP was defined as a cumulative adjusted odds ratio (cOR) less than 1 and a clinically meaningful effect as cOR less than 0.8. Of 941 participants randomized (473 to placebo and 468 to CCP), 556 were men (59.1%); median age was 63 years (IQR, 52-73); 373 (39.6%) were Hispanic and 132 (14.0%) were non-Hispanic Black. The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR<1] = 72%); the cOR for the secondary adjusted outcome was 0.92 (95% CrI, 0.74-1.16; P[cOR<1] = 76%). Exploratory subgroup analyses suggested heterogeneity of treatment effect: at day 28, cORs were 0.72 (95% CrI, 0.46-1.13; P[cOR<1] = 93%) for participants enrolled in April-June 2020 and 0.65 (95% CrI, 0.41 to 1.02; P[cOR<1] = 97%) for those not receiving remdesivir and not receiving corticosteroids at randomization. Median CCP SARS-CoV-2 neutralizing titer used in April to June 2020 was 1:175 (IQR, 76-379). Any adverse events (excluding transfusion reactions) were reported for 39 (8.2%) placebo recipients and 44 (9.4%) CCP recipients (P = .57). Transfusion reactions occurred in 2 (0.4) placebo recipients and 8 (1.7) CCP recipients (P = .06). In this trial, CCP did not meet the prespecified primary and secondary outcomes for CCP efficacy. However, high-titer CCP may have benefited participants early in the pandemic when remdesivir and corticosteroids were not in use. ClinicalTrials.gov Identifier: NCT04364737